How NAVLIN by EVERSANA Access Studio brings AI, trusted data, and expert workflows together
AI is rapidly becoming part of everyday work in pharma. Market Access teams are already using it to research and summarize evidence, explore competitors, draft content, and accelerate analysis.
However, giving every expert access to a powerful AI model does not automatically create a better or more consistent decision process.
Two experienced Market Access professionals can ask the same question and take very different approaches: using different sources, selecting different analogues, making different assumptions, or applying different methodologies. AI can make each of them faster, but it can also accelerate that variability.
And for important decisions, a good-looking AI answer is rarely enough. Teams need to understand the evidence behind it, the assumptions that were made, the methodology applied, and where expert judgment influenced the conclusion.
That is the gap NAVLIN by EVERSANA Access Studio is designed to fill.
Moving from AI Tools to AI-assisted Workflows
Access Studio is being designed around a simple idea:
Don’t just give AI a question. Give it a workflow.
Rather than starting with an empty prompt, Access Studio brings together AI, NAVLIN by EVERSANA data and insights, external evidence, analytical models and expert methodology within structured Market Access workflows.
The aim is not to remove the expert from the process. It is to give experts a stronger starting point and allow them to spend more time reviewing evidence, challenging assumptions, and making decisions.
Sources and assumptions remain visible; analysis can be reviewed and refined; and the reasoning developed through one project can become useful context for the next.
In other words, the goal is not simply AI-generated answers. It is decision-grade analysis.
What Does This Look Like in Practice?
Two of the first workflows illustrate the approach.
BD Explorer supports teams evaluating new assets and opportunities. Starting from an asset or TPP, it can help structure the journey through the disease landscape, standard of care, patient journey, unmet need, epidemiology, competition, relevant analogues, pricing and access potential, and ultimately commercial assessment.
Instead of researching each element independently, teams can work through a connected assessment where evidence, assumptions and expert input build on one another.
PICO Planner applies the same principle to evidence planning. Rather than simply asking AI to “create a PICO,” the workflow helps teams explore the clinical landscape, relevant comparators, endpoints and available evidence before refining the research question.
AI accelerates the work, but the methodology and expert judgment remain central to the process.
Connecting Expertise, Not Replacing It
Market Access decisions rarely belong to one function.
An asset assessment may involve epidemiology, Patient Insights, HEOR, Market Access, Pricing, Forecasting, and Finance. Those disciplines exist separately for good reasons, and each brings specialist expertise.
But the underlying decision does not necessarily follow the organizational chart.
Access Studio is therefore also an experiment in making those contributions more connected: allowing different experts to enter the same evolving workflow at the points where their expertise matters, rather than treating every stage as an isolated analysis.
The organization can remain specialized while the decision process becomes more connected.
Building the Next Generation of Market Access Workflows
We are still early in this journey.
BD Explorer and PICO Planner are two examples of how we are applying the approach, with additional workflows being developed across Market Access, pricing, reimbursement, evidence, and portfolio decision-making.
The common principle is straightforward:
Structured workflows + trusted evidence and data + AI and analytical models + expert judgment.
AI models will continue to improve rapidly. We believe the bigger opportunity is to build the processes around them that make those capabilities useful, transparent, and repeatable for Market Access teams.
That is what we are building with NAVLIN by EVERSANA Access Studio.
Connect with our experts to learn more.
Author Team
NAVLIN Price & Access Data is a powerful competitor intelligence tool that provides near real-time updates to drug price (list / net), reimbursement, tender and cost of treatment information at the indication level. Our…